Phase 3 DETERMINE Study in Dermatomyositis
Topline results from the study are on track to be reported in the second quarter of 2021.
- Primary Endpoint: American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2016 Total Improvement Score (TIS) in Adult Dermatomyositis & Polymyositis at Week 28, lenabasum taken twice daily vs. placebo (n = 176)
- Key Secondary Endpoints: Definition of Improvement, Investigator Global Assessment scale of skin activity, and Cutaneous Dermatomyositis Activity and Severity Index activity score
- For Complete Study Details, Please View the Study Listing on clinicaltrials.gov: ClinicalTrials.gov Identifier: NCT03813160
Medical professionals may email us at DMphysicians@corbuspharma.com for more information about study participation.
Patients, caregivers or patient advocates looking for additional information may email us at DMpatients@corbuspharma.com.
For any other inquiries, please see our Contact Us page.